Status:
COMPLETED
Efficacy of Rostafuroxin in the Treatment of Essential Hypertension
Lead Sponsor:
sigma-tau i.f.r. S.p.A.
Conditions:
Essential Hypertension
Eligibility:
All Genders
30-59 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of essential hypertension and to determine the best effective dose to be administered in the general hypertensive p...
Detailed Description
Elevated arterial pressure is probably the most important public health problem. about 30% of the world adult population are affected by hypertension in industrialised countries. Development of a phar...
Eligibility Criteria
Inclusion
- Patients with grade 1 or 2 of essential hypertension
- Less than 3 risk factors (age \> 55 if male, smoking, dyslipidemia, family history of CV disease occurring before 55 years in men and 65 in women
- Naive patients or currently on monotherapy or one combination tablet
- SBP between 140 and 169 mmHg
Exclusion
- Atrial fibrillation or left or right VBBB
- Left ventricular hypertrophy
- Significant renal or hepatic disease
- Obesity \> 30kg/m2
- Diabetes mellitus
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
438 Patients enrolled
Trial Details
Trial ID
NCT00415038
Start Date
February 1 2005
End Date
August 1 2007
Last Update
June 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Catholic University of Leuven - Laboratory of Hypertension, Dept. of Molecular and Cardiov. Research - Campus Gasthuisberg
Leuven, Belgium, B-3000